1 Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by Florida Department of Children and Families Substance Abuse and Mental Health Program Office funding.
2 Learning Objectives Give accurate data on the extent of the opioid crisis in 2014, including opioid use, admissions, and death by overdose Discuss trends in opiate use and consequences associated with use and addiction Explain the basic pharmacology and side effects/risks associated with Vivitrol (Extended Release Injectable Naltrexone) and Suboxone Describe Medication Assisted Treatment (MAT) for pregnant women and HIV drug users Cite research that supports the use of MAT Describe organizational experiences and outcomes associated with using MAT within a 12 Step abstinence based program Show how MAT can be compatible with a 12 Step abstinenceoriented treatment system
3 Annual Numbers of New Nonmedical Users of Psychotherapeutics: Source: Substance Abuse & Mental Health Services Administration(SAMHSA) National Survey on Drug Use and Health (NSDUH) Survey,
4 Opioid Prescriptions: Total Number Dispensed by U.S. Retail Pharmacies: Source: SDI Vector One : National (VONA)
6 A Frightening Trend: Past Year Initiates of Specific Illicit Drugs Among Persons Aged 12 or Older, 2010 Source: SAMHSA NSDUH Survey, 2010
7 Poll Question #1 On a scale of 1 5 (5 being most critical and 1 being not critical at all), please rate what you believe the severity of the opioid epidemic to be in your community?
8 Prescription Opioid Crisis Four fold increase in treatment admissions (U.S ) Overdose deaths have increased dramatically (U.S. 3,000 in ,500 in 2011) Over 125,000 opioid overdose deaths have occurred in the U.S. in the past decade
9 Prescription Opioid Crisis In 2010, 60% of drug overdose deaths (22,134) involved prescribed medications. Drug overdose became the number one accidental cause of death. Fueled by the dramatic increase in opioid overdose deaths. Prescription opioid overdoses for those 15 and older: 1.6 deaths per 100,000 in increasing to 6.6 deaths per 100,000 in Source: Center for Disease Control
10 Prescription Opioid Crisis Drug overdose deaths ( ) Increased 5 fold in women Increased 3.6 fold in men (more men die overall) Prescription opioids killed at least 9,000 women in 2010, a rate of 18 per day. Source: Journal of the American Medical Association (JAMA), August 28, 2013
11 Rates* of Opioid Pain Reliever (OPR) Overdose Death, OPR Treatment Admissions and Kilograms of OPR Sold: United States, * Age adjusted rates per 100,000 population for OPR deaths, crude rates per 10,000 population for OPR abuse treatment admissions, and crude rates per 10,000 population for kilograms of OPR sold. Source:
12 Readily Available
13 The Changing Face of Heroin (Treatment Seeking Subjects) 1960 s Predominantly men (82.5% male) Average age of onset: 16.5 First opioid of abuse heroin (80%) Primarily urban population Whites and non whites equally represented Men and women are equally involved Average age of onset increased to 22.9 years 75% started with prescription opioids More likely to be from non urban area (75.2%) 90% white Source: The Changing Face of Heroin Use in the US, JAMA Psychiatry 2014;366
14 Poll Question #2 In your practice, what has been the trend in the increase of opioid overdose deaths related to gender?
16 Vivitrol : Extended Release Injectable Naltrexone Opioid receptor blocker (opioid antagonist) Administered by intramuscular injection, once a month Prevents binding of opioids to receptors, eliminating intoxication and reward Basic Overview Awareness (Opioid Primer) Has been shown to reduce craving and relapse Has no abuse potential
17 Side Effects/Risks Vivitrol: Extended Release Injectable Naltrexone Injection site pain, swelling, blisters, open wound Liver enzyme abnormalities Serious allergic reactions Minor side effects: dizziness, depressed mood, nausea, tiredness, fatigue Attempts to over ride opioid receptor blockade
18 Suboxone : Buprenorphine/Naloxone A partial opioid agonist, a maintenance treatment Administered sublingually on a daily basis Binds to and activates opioid receptors, but not to the same degree as true opioid agonists Improves treatment retention, and reduces craving and relapse Illicit use and diversion are likely
19 Side Effects/Risks Suboxone: Buprenorphine/Naloxone Respiratory depression (benzodiazepines) Sleepiness, dizziness Liver enzyme abnormalities Serious allergic reactions Minor side effects: headache, nausea, sweating Simultaneous use of other opioids
20 Injectable Extended Release Naltrexone Naltrexone Placebo 1. Weeks abstinent 90% 35% 2. Opioid free days 99.2% 60.4% 3. Mean change in 10.1% 0.7% craving 4. Median retention 168 days 96 days Source: Lancet 2011; 377:
21 Buprenorphine/Naloxone Treatment for Prescription Opioid Dependence: Study Two phase study: 2 week Bup/Nal stabilization, 2 week taper, 8 week followup 12 week Bup/Nal stabilization, 4 week taper, 8 week followup 653 treatment seeking outpatients with opioid dependence Randomized to: Standard medication management (SMM) SMM and opioid dependence counseling All participants were referred to self help groups Source: Arch. Gen. Psych. Vol 68(No.12), Dec 2011
22 Buprenorphine Naloxone Results Phase 1 Only 6.6% were successful No difference between SMM and SMM with opioid counseling Phase % successful while using bup nal No difference between SMM and SMM with opioid counseling Success rates after completion: 8.6% Source: Arch. Gen. Psych. Vol 68(No.12), Dec 2011
23 Recognition A large segment of the opioid dependent population was not effectively being reached and treatment was not adequate. This high risk population needs the opportunity to engage in long term recovery.
24 Hazelden Betty Ford Foundation s Response Alter the entire treatment of opioid dependence within our system: COR 12. Incorporate two evidence based medications into treatment protocols for opioid dependence: naltrexone and buprenorphine. Study the results. Our goal will be discontinuation of medication as patients become established in long term recovery.
25 Organizational Change Process Team established Literature review White paper Plan for organization Training forums Communication
26 Program Development Clinical Practice Protocols Education Opioid Dependency Group Stigma Management Initiatives
27 Residential Treatment Outpatient Treatment Long Term Approach: Recovery Management Opioid Dependency Group MORE Case Management Basic Overview Awareness (Opioid Primer) Basic Overview Awareness (Opioid Primer)
28 Compatibility with Twelve Step Abstinence Based Model Extended release injectable naltrexone is already used for alcohol dependence. Buprenorphine/naloxone can induce intoxication and is abused, but primarily for detox or to get by. Twelve Step treatment models tend to avoid buprenorphine/naloxone. Buprenorphine/Naloxone protocols will blur the line of abstinence based programming, so the goal will always be discontinuation once long term recovery is established.
29 Hazelden Betty Ford Foundation Research Study Naturalistic Compare the two medications in practice Examine the outcomes of medications in combination with robust Twelve Step, abstinence based, treatment Examine predictors for response to the medications Examine length of treatment with the medications
30 COR 12 Patient Participation Admissions to Center City Primary 1/1/13 12/31/13 Total number with opioid dependence COR 12: No Medication 38 9% COR 12: Buprenorphine/Naloxone 30 7% COR 12: Extended Release Naltrexone 46 11%
31 COR 12 Results % of opioid dependent patients who were not in COR 12 discharged atypically. Only 11.11% of opioid dependent patients enrolled in COR 12 discharged atypically. COR 12 participants were 46% less likely to discharge atypically. 6 former opioid dependent patients deceased in 2013; Zero were COR 12 participants.
32 Medication Assisted Treatment and Pregnancy Pregnant women who are dependent on heroin or prescription opioids can safely use MAT. Methadone and buprenorphine are considered appropriate, safe treatments for pregnant women with opioid dependence. Methadone and buprenorphine are classified as pregnancy category C medications (adverse effects have been seen in animals; human studies have not yet fully defined the risk, but the potential benefits may warrant use despite the risk). Methadone remains the most common treatment due to extensive experience (since the late 1970 s). Both medications protect the fetus and newborn from the risk of sudden opioid withdrawal.
33 Poll Question #3 Can pregnant women be safely treated for opioid dependence using a medication assisted treatment method?
34 Medication Assisted Treatment for HIV Patients 30% of HIV infections are related to drug use and associated behaviors In an increasing number of studies, medication assisted treatment of drug abuse and dependence has been shown to be an important HIV prevention intervention Medication assisted treatment plays an important role in the prevention, care, and treatment of HIV infected individuals who also abuse drugs Source: National Center for Biotechnology Information, Medication assisted treatment in the treatment of drug abuse and dependence in HIV/AIDS infected drug users, 2009
35 What Can Be Done?
36 Universal Precautions in Chronic Pain Treatment 1. Diagnosis with reasonable differential 2. Detailed psychological assessment, including risk of addiction 3. Rational non opioid therapeutic trial 4. Pre trial assessment of pain and function 5. Informed consent (verbal and written/signed)
37 Universal Precautions in Chronic Pain Treatment 6. Treatment agreement (verbal and written/signed) 7. Careful, time limited trial of opioid therapy 8. Reassessment of pain, function and diagnosis 9. Regular assessment of aberrant behavior 10.DOCUMENT Source: Gourlay 2004
38 Primary Care Triage of Chronic Pain Patients Primary Care No history of substance use disorder No major psychiatric comorbidity Primary Care with Consultation Increased risk patient: In recovery from addiction, family history, aberrant behavior, current psychiatric disorder Referral to Tertiary Care (Addiction Medicine Specialist) Active addiction Major untreated psychiatric disorder
39 Center for Disease Control Agenda Support and Develop Surveillance Systems: Prescription Drug Monitoring Programs (PDMP s) Educate Patients, the Public and Medical Providers Policy Change
40 Training Federal Response Tracking and Monitoring (PDMP s) Proper Medication Disposal Enforcement Source: Epidemic: Responding to America s Prescription drug Crisis 2011 (ONDCP)
41 What Can Healthcare Professionals Do? Screen for addiction and alcoholism Refer to an addiction specialist just like any other medical specialty Examine your prescribing practices Learn more about treatment of chronic pain Learn more about pain and addiction Prevent diversion in your medical setting Naloxone for overdose treatment
42 What Else Can You Do? Advocate for state and federal law changes Educate students, parents, local community, state, law enforcement, legislators, physicians, etc. Involve your professional organizations Create accountability for the pharmaceutical industry Support prescription monitoring programs Support the federal agenda Please Commit to Action!
43 Summary An opioid use crisis exists in the U.S.; opioid use has escalated since the mid 90 s with associated increases in emergency room visits, treatment admissions and overdose deaths. Medication Assisted Treatment for opioid dependence is effective, safe and can be aligned with abstinence based, Twelve Step programs to engage more people in long term recovery. We have many opportunities to alter the course of this crisis and limit the destruction.
The ABCs of Medication Assisted Treatment J E F F R E Y Q U A M M E, E X E C U T I V E D I R E C T O R C O N N E C T I C U T C E R T I F I C A T I O N B O A R D The ABCs of Medication Assisted Treatment
Opioid/Opiate Dependent Pregnant Women The epidemic, safety, stigma, and how to help. Presented by Lisa Ramirez MA,LCDC & Kerby Stewart MD The prescription painkiller epidemic is killing more women than
Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence
Neurobiology and Treatment of Opioid Dependence Nebraska MAT Training September 29, 2011 Top 5 primary illegal drugs for persons age 18 29 entering treatment, % 30 25 20 15 10 Heroin or Prescription Opioids
Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing
Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society
Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,
Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA
Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious
This is a fact in the treatment of alcohol and drug abuse: Patients who do well in treatment do well in any treatment and patients who do badly in treatment do badly in any treatment. One example: Chapman
Prescription Drug Abuse: Recognition, Intervention, and Prevention Nicholas Reuter Division of Pharmacologic Therapy Center for Substance Abuse Treatment Substance Abuse and Mental Health Services Administration
Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl
Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction March 3, 2008 By: David Rinaldo, Ph.D., Managing Partner, The Avisa Group In this FAQ What medications are currently
Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,
Governor s Cabinet Opiate Action Team Promoting Wellness and Recovery John R. Kasich, Governor Tracy J. Plouck, Director Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio November 14,
Substitution Therapy for Opioid Dependence The Role of Suboxone Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015 Objectives Recognize the options available in treating opioid
Vivitrol Pilot Study: SEMCA/Treatment Providers Collaborative Efforts with the treatment of Opioid Dependent Clients Hakeem Lumumba, PhD, CAADC SEMCA Scott Schadel, MSW, LMSW, CAADC HEGIRA PROGRAMS, INC.
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Sidarth Wakhlu,M.D. Addiction Team Leader North Texas VA Health Care System Addiction Psychiatry Fellowship Director Associate Professor Of Psychiatry
Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary Which of the following is an
Opioid Addiction and Methadone: Myths and Misconceptions Nicole Nakatsu WRHA Practice Development Pharmacist Learning Objectives By the end of this presentation you should be able to: Understand how opioids
Office-based Treatment of Opioid Dependence with Buprenorphine David A. Fiellin, M.D Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine Dr. Fiellin s Disclosures
Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas David Lakey, MD Commissioner, Department of State Health Services Lauren Lacefield Lewis Assistant Commissioner,
Ohio Legislative Service Commission Bill Analysis Brian D. Malachowsky H.B. 378 130th General Assembly () Reps. Smith and Sprague BILL SUMMARY Prohibits a physician from prescribing or personally furnishing
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently asked questions What is Naltrexone? Naltrexone is a prescription drug that completely blocks the effects of all opioid drugs
Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective Dale K. Adair, MD Medical Director/Chief Psychiatric Officer OMHSAS 1 Treatment and Interventions for
Presenters Erin Hall MSOT Hon. Kyle B. Haskins Closed Doors or Welcome Mat? Opening the Way for Medication-Assisted Treatment in Family Drug Courts Oklahoma Specialty Court Conference Thursday September
John R. Kasich, Governor Orman Hall, Director 2 3 Epidemics of unintentional drug overdoses in Ohio, 1979-2011 1,2,3 1800 1600 1400 1200 1000 800 Prescription drugs are causing a larger overdose epidemic
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate
Web-Based Resources Locating Treatment http://dpt2.samhsa.gov/treatment/ -- This is the Substance Abuse and Mental Health Services Administration s (SAMHSA) page for locating both public and private opiate
Buprenorphine Therapy in Addiction Treatment Ken Roy, MD, FASAM Addiction Recovery Resources, Inc. River Oaks Hospital Tulane Department of Psychiatry www.arrno.org Like Minded Doc What is MAT? Definition
Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San
Populations at risk for opioid overdose Len Paulozzi, MD, MPH Division of Unintentional Injury Prevention National Center for Injury Prevention and Control Centers for Disease Control and Prevention April
PRESCRITPION DRUG ABUSE: AN EPIDEMIC What is Addiction? By: Lon R. Hays, M.D., M.B.A. Professor and Chairman Department of Psychiatry University of Kentucky Healthcare Addiction is a primary, chronic disease
Heroin Overdose Trends and Treatment Options Neil A. Capretto, D.O., F.A.S.A.M. Medical Director Type date here www.gatewayrehab.org Drug Overdose Deaths Increasing in Allegheny County Roberta Lojak holds
Beyond SBIRT: Integrating Addiction Medicine into Primary Care Community Clinic Association of Los Angeles County 14 th Annual Health Care Symposium March 6, 2015 Keith Heinzerling MD, Karen Lamp MD; Allison
Sarah Akerman MD Assistant Professor of Psychiatry Director of Addiction Services Geisel School of Medicine/Dartmouth-Hitchcock Medical Center OVERVIEW OF MEDICATION ASSISTED TREATMENT Conflicts of Interest
Tufts Health Care Institute Program on Opioid Risk Management Pharmacotherapy for Prescription Opioid Addiction: Implications for Pain Management June 10 and 11, 2011 Executive Summary Introduction Opioid
Dependence and Addiction Marek C. Chawarski, Ph.D. Yale University David Metzger, Ph.D. University of Pennsylvania Overview Heroin and other opiates The disease of heroin addiction or dependence Effective
TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment
Testimony of The New York City Department of Health and Mental Hygiene before the New York City State Assembly Committee on Alcoholism and Drug Abuse on Programs and Services for the Treatment of Opioid
Treatment of Prescription Opioid Dependence Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse McLean Hospital, Belmont, MA Professor of Psychiatry, Harvard Medical School, Boston, MA Prescription
Drug Court EPIDEMIC In the 10 years (1997 2007) the per capita retail purchases of Methadone, Hydrocodone and Oxycodone in the United States increased 13-fold, 4-fold and 9-fold, respectively. 4.6 % OF
Joel Millard, DSW, LCSW Dave Felt, LCSW 1. Provide an overview of the effectiveness of medication assisted treatment, to include a discussion of the different types of medications and how they are used
National Perspectives in Medication Assisted Treatment Addiction Medicine Asheville March 21,2014 Melinda Campopiano, MD Medical Officer Substance Abuse & Mental Health Services Administration Guten Appetit
Use of Vivitrol for Alcohol and Opioid Addiction Ken Bachrach, Ph.D. Clinical Director, Tarzana Treatment Centers, Inc. email@example.com What is Vivitrol? An injectable from of naltrexone, which
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Mark Fisher Program Administrator State Opioid Treatment Adminstrator Kentucky Division of Behavioral Health OBJECTIVES Learn about types of opioids and
DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please
Developing Medications to Treat Addiction: Implications for Policy and Practice Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine
ISSUE DATE SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Opiate Dependence Treatments Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical
FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma Background A growing opiate abuse epidemic has highlighted the need for effective treatment options. This study documents
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
Treatment for Addiction in the Community Reduces Drug Use, Crime and Recidivism Richard A. Rawson, Ph.D, Professor Semel Institute for Neuroscience and Human Behavior David Geffen School of Medicine University
ISSUE DATE September 4, 2015 SUBJECT EFFECTIVE DATE September 9, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Opiate Dependence Treatments, Oral Buprenorphine Agents - Pharmacy
Substance Abuse During Pregnancy: Moms on Meds Jennifer Anderson Maddron, M.D LeConte Womens Healthcare Associates 2010 National Survey on Drug Use and Health An estimated 4.4% of pregnant women reported
Medication-Assisted Addiction Treatment Molly Carney, Ph.D., M.B.A. Executive Director Evergreen Treatment Services Seattle, WA What is MAT? MAT is the use of medications, in combination with counseling
Reforming the Response To Substance Use: A Drug Policy for the 21 st Century 2015 NASADAD MEETING Charleston, SC June 2, 2015 David Mineta, Deputy Director Office of Demand Reduction Office of National
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
Medication Assisted Treatment Tanya Hiser, MS, LPC State Opioid Treatment Authority Bureau Of Prevention, Treatment, & Recovery State of Wisconsin Elizabeth Collier, MSW, CSAC, ICS, LCSW TANF Best Practice
Ever wish you could... Quit using heroin? Protect yourself from HIV infection? Get healthier? Good News: Medical treatments called opioid (oh-pee-oyd) maintenance can help you! Injecting heroin puts you
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call the
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)
Opioid Addiction & Corrections Medication Assisted Treatment in the Connecticut Department of Correction April 30, 2015--CJPAC Kathleen F. Maurer, MD, MPH, MBA Medical Director and Director of Health and
Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation Cynthia Caporizzo, Senior Criminal Justice Advisor, Office of National Drug Control Policy (ONDCP) - Review of the administration
opiates alcohol 27 opiates and alcohol 30 April 2016 drug addiction signs 42 ed #1 123 Drug Rehab Centers in New Jersey 100 Top 10 380 effects of alcohol in the brain 100 Top 30 698 heroin addiction 100
Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,
Collective Action Issue Brief #2 Updated June 2014 PRESCRIPTION PAIN MEDICATION MISUSE WHAT WE KNOW The misuse and abuse of prescription drugs has become a leading cause of harm among New Hampshire adults,
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently Asked Questions What is Naltrexone? Naltrexone is a prescription drug that effectively blocks the effects of heroin, alcohol,
visited on Page 1 of 5 LEARN MORE (HTTP://WWW.NAMI.ORG/LEARN-MORE) FIND SUPPORT (HTTP://WWW.NAMI.ORG/FIND-SUPPORT) GET INVOLVED (HTTP://WWW.NAMI.ORG/GET-INVOLVED) DONATE (HTTPS://NAMI360.NAMI.ORG/EWEB/DYNAMICPAGE.ASPX?
Narcotic Replacement Therapy Policy San Mateo County Alcohol and Other Drug Services Lea Goldstein, Ph.D. Brian Greenberg, Ph.D. The Narcotic Replacement Therapy (NRT) Policy Narcotic replacement programs
Triage, Assessment & Treatment Methadone 101/Hospitalist Workshop Launette Rieb, MSc, MD, CCFP, FCFP Clinical Associate Professor, Dept. Family Practice UBC American Board of Addiction Medicine Certified
The Heroin and Prescription Drug Abuse Prevention and Reduction Act Section by Section TITLE I: PREVENTION SUBTITLE A- PRESCRIBER EDUCATION PRACTITIONER EDUCATION This subtitle requires practitioners who
Best Practices in Opioid Dependence Treatment Anthony L. Jordan Health Center Linda Clark, MD, MS Medical Director Alana Ramos, BS Suboxone Clinic Manager Case Studies Nicole White female 27 years of age
Prescription drug abuse trends Minnesota s Prescription Monitoring Program Carol Falkowski Drug Abuse Dialogues www.drugabusedialogues.com Barbara Carter, Manager MN Board of Pharmacy www.pmp.pharmacy.state.mn.us
A Drug Policy for the 21st Century April 26, 2014 California Association for Alcohol and Drug Educators (CAADE) Conference Integrating Mental Health and Substance Use Disorder Services David K. Mineta,
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines
MAT Disclosures & Consents 1 of 6 Authorization & Disclosure ***YOUR INSURANCE MAY NOT PAY FOR ROUTINE SCREENING*** *** APPROPRIATE SCREENING DIAGNOSES MUST BE PROVIDED WHEN INDICATED*** Urine Drug Test
Naltrexone and Alcoholism Treatment Test Following your reading of the course material found in TIP No. 28. Please read the following statements and indicate the correct answer on the answer sheet. A score
H-SOAP STUDY Hospital-based Services for Opioid- and Alcohol-addicted Patients Meldon Kahan, Anita Srivastava, Kate Hardy, Sarah Clarke Canadian Society of Addiction Medicine 2014 October 17, 2014 1 Few
BULLETIN INTELLIGENCE Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III drug has been made available for use
Opioids for Chronic Pain and Addiction Treatment Joseph Merrill M.D., M.P.H. University of Washington February 24, 2012 Outline for Today Opioids for pain treatment Trends Problems High dose prescribing
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE 201 KAR 9:260. Professional standards for prescribing and dispensing controlled substances.